FUSN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 7.75%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Fusion Pharmaceuticals Insider Trading History Chart

Fusion Pharmaceuticals Share Price & Price History

^$21.55

+0.30 (1.20%)

As of 06/4/2024 01:00 AM ET

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Fusion Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/11/2022	Steven Gannon	Director	Buy	44,400	$2.03	$90,132.00	56,400
4/27/2022	John Valliant	CEO	Sell	4,511	$6.03	$27,201.33	318,147
4/25/2022	John Valliant	CEO	Sell	2,036	$6.03	$12,277.08	324,805
4/20/2022	John Valliant	CEO	Sell	367	$6.02	$2,209.34	327,763
4/13/2022	John Valliant	CEO	Sell	11,994	$6.41	$76,881.54	328,130
4/11/2022	John Valliant	CEO	Sell	2,600	$7.37	$19,162.00	358,379
4/8/2022	John Valliant	CEO	Sell	826	$7.52	$6,211.52	360,979
4/6/2022	John Valliant	CEO	Sell	100	$7.58	$758.00	360,979
3/30/2022	John Valliant	CEO	Sell	300	$7.52	$2,256.00
3/28/2022	John Valliant	CEO	Sell	9,600	$7.55	$72,480.00
3/25/2022	John Valliant	CEO	Sell	500	$7.42	$3,710.00
3/23/2022	John Valliant	CEO	Sell	100	$7.50	$750.00
3/21/2022	John Valliant	CEO	Sell	1,500	$7.47	$11,205.00
3/17/2022	John Valliant	CEO	Sell	900	$7.51	$6,759.00
3/7/2022	John Valliant	CEO	Sell	3,100	$6.99	$21,669.00
3/4/2022	John Valliant	CEO	Sell	8,400	$7.32	$61,488.00
2/28/2022	John Valliant	CEO	Sell	3,100	$7.40	$22,940.00
2/24/2022	John Valliant	CEO	Sell	2,500	$7.41	$18,525.00
2/22/2022	John Valliant	CEO	Sell	4,100	$7.85	$32,185.00
2/17/2022	John Valliant	CEO	Sell	1,700	$7.98	$13,566.00
2/15/2022	John Valliant	CEO	Sell	12,600	$8.33	$104,958.00

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

SEC Filings (Institutional Ownership Changes) for Fusion Pharmaceuticals (NASDAQ:FUSN)

72.85% of Fusion Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Fusion Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/20/2024	Virtu Financial LLC	28,917	$0.62M	0.0%	N/A	0.034%
5/20/2024	Bluefin Capital Management LLC	10,000	$0.21M	0.0%	N/A	0.012%
5/16/2024	Jane Street Group LLC	633,932	$13.52M	0.0%	+2,153.4%	0.745%
5/16/2024	California State Teachers Retirement System	39,041	$0.83M	0.0%	N/A	0.046%
5/16/2024	KRYGER CAPITAL Ltd	100,284	$2.14M	0.4%	N/A	0.118%
5/16/2024	Beryl Capital Management LLC	16,191	$0.35M	0.4%	N/A	0.019%
5/15/2024	GABELLI & Co INVESTMENT ADVISERS INC.	115,750	$2.47M	0.4%	N/A	0.136%
5/15/2024	Gabelli Funds LLC	146,150	$3.12M	0.0%	N/A	0.172%
5/15/2024	Gamco Investors INC. ET AL	11,450	$0.24M	0.0%	N/A	0.013%
5/14/2024	Natixis	99,000	$2.11M	0.0%	N/A	0.116%
5/10/2024	Maso Capital Partners Ltd	150,000	$3.20M	2.4%	N/A	0.177%
5/9/2024	Chicago Capital Management LLC	170,200	$3.63M	3.8%	N/A	0.201%
5/9/2024	Blair William & Co. IL	779,202	$16.61M	0.1%	-21.6%	0.918%
5/8/2024	ProShare Advisors LLC	17,623	$0.38M	0.0%	N/A	0.021%
5/7/2024	Swiss National Bank	85,700	$1.83M	0.0%	N/A	0.101%
4/30/2024	Privium Fund Management B.V.	251,158	$5.36M	1.5%	+77.2%	0.296%
4/29/2024	China Universal Asset Management Co. Ltd.	13,920	$0.30M	0.0%	+66.2%	0.016%
3/5/2024	Wellington Management Group LLP	744,474	$7.15M	0.0%	N/A	1.028%
2/15/2024	Forefront Analytics LLC	16,715	$0.16M	0.1%	-50.4%	0.023%
2/14/2024	Avidity Partners Management LP	6,500,328	$62.47M	2.3%	+12.4%	8.978%
2/14/2024	Superstring Capital Management LP	45,801	$0.44M	0.3%	N/A	0.063%
2/13/2024	Tower Research Capital LLC TRC	3,008	$29K	0.0%	+2,064.0%	0.004%
2/13/2024	NEOS Investment Management LLC	30,939	$0.30M	0.0%	+76.9%	0.043%
2/7/2024	Jump Financial LLC	86,199	$0.83M	0.0%	N/A	0.119%
2/1/2024	New York State Common Retirement Fund	6,630	$64K	0.0%	N/A	0.009%
2/1/2024	Jennison Associates LLC	301,020	$2.89M	0.0%	N/A	0.416%
2/1/2024	Signaturefd LLC	2,949	$28K	0.0%	+883.0%	0.004%
1/31/2024	abrdn plc	21,697	$0.21M	0.0%	N/A	0.030%
1/31/2024	Federated Hermes Inc.	10,886,153	$104.62M	0.3%	+1.9%	15.034%
1/30/2024	HealthInvest Partners AB	125,000	$1.20M	0.9%	N/A	0.173%
1/24/2024	China Universal Asset Management Co. Ltd.	8,376	$80K	0.0%	N/A	0.012%
1/16/2024	Raymond James Financial Services Advisors Inc.	31,145	$0.30M	0.0%	N/A	0.043%
1/12/2024	Yarbrough Capital LLC	76,872	$0.74M	0.0%	N/A	0.106%
11/14/2023	Avidity Partners Management LP	5,781,850	$15.03M	0.6%	+1.4%	7.985%
11/13/2023	Federated Hermes Inc.	10,683,789	$27.78M	0.1%	+0.5%	14.755%
11/13/2023	FMR LLC	4,177,848	$10.86M	0.0%	-10.8%	5.770%
11/8/2023	Forefront Analytics LLC	33,685	$88K	0.0%	+67.8%	0.049%
10/27/2023	Eagle Health Investments LP	579,769	$1.51M	0.3%	-14.8%	0.840%
8/24/2023	Perceptive Advisors LLC	2,751,395	$12.85M	0.4%	-0.3%	3.988%
8/15/2023	Sphera Funds Management LTD.	1,329,258	$6.21M	1.0%	+3.6%	1.926%
8/14/2023	Eagle Health Investments LP	680,370	$3.18M	0.6%	N/A	0.986%
8/11/2023	Artal Group S.A.	1,725,000	$8.06M	0.2%	-12.7%	2.500%
5/15/2023	Ghost Tree Capital LLC	350,000	$1.32M	0.4%	N/A	0.554%
5/15/2023	Sio Capital Management LLC	246,036	$0.93M	0.5%	-5.5%	0.389%
5/8/2023	Federated Hermes Inc.	5,849,100	$22.05M	0.1%	+81.4%	9.253%
5/1/2023	Virtu Financial LLC	13,084	$49K	0.0%	N/A	0.021%
2/15/2023	Braidwell LP	2,000,000	$6.30M	0.2%	N/A	4.468%
2/10/2023	Tekla Capital Management LLC	43,394	$0.14M	0.0%	-57.4%	0.097%
11/15/2022	Federated Hermes Inc.	3,174,100	$9.56M	0.0%	+1.6%	7.091%
11/14/2022	Point72 Asset Management L.P.	310,068	$0.93M	0.0%	-5.7%	0.693%
11/14/2022	RA Capital Management L.P.	659,992	$1.99M	0.0%	N/A	1.474%
11/14/2022	UBS Oconnor LLC	17,286	$52K	0.0%	N/A	0.039%
11/8/2022	Sofinnova Investments Inc.	117,099	$0.35M	0.0%	+50.0%	0.270%
11/4/2022	Prudential Financial Inc.	14,600	$44K	0.0%	N/A	0.034%
11/2/2022	Victory Capital Management Inc.	50,390	$0.15M	0.0%	-72.2%	0.116%
11/1/2022	Tekla Capital Management LLC	101,931	$0.61M	0.0%	+134.9%	0.235%
9/16/2022	Federated Hermes Inc.	3,124,100	$7.78M	0.0%	+2.3%	7.200%
8/15/2022	Pivotal bioVenture Partners Investment Advisor LLC	1,560,982	$3.89M	2.0%	-2.3%	3.597%
5/4/2022	Victory Capital Management Inc.	183,690	$1.30M	0.0%	-26.6%	0.424%
2/25/2022	AlphaCentric Advisors LLC	100,000	$0.42M	0.1%	N/A	0.232%
2/14/2022	Perceptive Advisors LLC	1,227,017	$5.12M	0.1%	-2.2%	2.849%
2/14/2022	Point72 Asset Management L.P.	1,048,956	$4.37M	0.0%	+22.3%	2.436%
2/7/2022	Victory Capital Management Inc.	250,380	$1.04M	0.0%	-6.5%	0.581%
12/3/2021	Perceptive Advisors LLC	1,254,607	$9.94M	0.1%	-29.3%	2.913%
11/15/2021	Point72 Asset Management L.P.	858,012	$6.80M	0.0%	-2.0%	1.992%
11/15/2021	Sectoral Asset Management Inc	38,198	$0.30M	0.0%	N/A	0.089%
11/12/2021	Johnson & Johnson	3,670,516	$29.07M	2.6%	N/A	8.523%
11/9/2021	BlackRock Inc.	414,256	$3.28M	0.0%	-11.9%	0.963%
11/2/2021	Victory Capital Management Inc.	267,703	$2.12M	0.0%	-0.7%	0.622%
8/17/2021	Woodline Partners LP	154,597	$1.25M	0.0%	+24.1%	0.364%
8/17/2021	Perceptive Advisors LLC	1,775,167	$14.34M	0.2%	-9.0%	4.181%
8/16/2021	Point72 Asset Management L.P.	875,141	$7.07M	0.0%	+16.7%	2.061%
8/16/2021	Perceptive Advisors LLC	1,775,167	$14.34M	0.2%	-9.0%	4.181%
8/16/2021	Federated Hermes Inc.	597,841	$4.83M	0.0%	+5.8%	1.408%
8/16/2021	Goldman Sachs Group Inc.	18,221	$0.15M	0.0%	+29.5%	0.043%
8/13/2021	Adams Street Partners LLC	2,973,744	$24.03M	5.0%	-0.5%	7.004%
8/13/2021	FMR LLC	3,184,209	$25.73M	0.0%	+1.5%	7.500%
8/11/2021	BlackRock Inc.	470,303	$3.80M	0.0%	-41.8%	1.108%
8/3/2021	Victory Capital Management Inc.	269,623	$2.18M	0.0%	-5.6%	0.635%
5/18/2021	Millennium Management LLC	10,726	$0.12M	0.0%	-76.9%	0.025%
5/18/2021	Point72 Asset Management L.P.	750,000	$8.04M	0.0%	+36.4%	1.766%
5/18/2021	Morgan Stanley	76,171	$0.82M	0.0%	+90.7%	0.179%
5/17/2021	Perceptive Advisors LLC	1,950,167	$20.91M	0.3%	-12.8%	4.593%
5/17/2021	Woodline Partners LP	124,594	$1.34M	0.0%	+135.9%	0.293%
5/13/2021	Federated Hermes Inc.	565,000	$6.06M	0.0%	+7.6%	1.331%
5/10/2021	Adams Street Partners LLC	2,989,644	$32.05M	5.1%	-14.4%	7.044%
5/7/2021	BlackRock Inc.	807,536	$8.66M	0.0%	-2.8%	1.903%
5/7/2021	Altfest L J & Co. Inc.	10,139	$0.11M	0.0%	N/A	0.024%
5/4/2021	Victory Capital Management Inc.	285,678	$3.06M	0.0%	+59.1%	0.673%
3/12/2021	DekaBank Deutsche Girozentrale	13,000	$0.16M	0.0%	N/A	0.031%
3/2/2021	Norges Bank	50,000	$0.59M	0.0%	N/A	0.120%
2/16/2021	Clough Capital Partners L P	399,399	$4.69M	0.3%	-0.8%	0.957%
2/12/2021	Caas Capital Management LP	23,148	$0.27M	0.0%	-60.4%	0.055%
2/12/2021	Federated Hermes Inc.	525,000	$6.17M	0.0%	+2.9%	1.258%
2/9/2021	Pivotal bioVenture Partners Investment Advisor LLC	1,598,379	$18.78M	6.2%	N/A	3.831%
2/5/2021	BlackRock Inc.	830,737	$9.76M	0.0%	+80.6%	1.991%
2/1/2021	Victory Capital Management Inc.	179,524	$2.11M	0.0%	+18.4%	0.430%
12/30/2020	Deerfield Management Company L.P. Series C	972,046	$11.68M	0.2%	-22.7%	2.330%
11/13/2020	Morgan Stanley	26,693	$0.32M	0.0%	-96.0%	0.064%
11/12/2020	Federated Hermes Inc.	510,000	$6.13M	0.0%	+59.4%	1.224%

Data available starting January 2016

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Today's Range

Now: $21.55

$21.55

50 Day Range

MA: $21.50

$21.38

$21.55

52 Week Range

Now: $21.55

$2.31

$21.60

Volume

N/A

Average Volume

1,692,620 shs

Market Capitalization

$1.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

When it comes to NVDA… “acceleration cycles” are the key

From DTI | Ad

Use this link to see Nvidia Unchained right away!